Focus: ZyVersa Therapeutics is a public specialty pharmaceutical company headquartered in Florida focused on neurology and rare disease therapeutics. The company is in early-stage development with minimal commercial revenue and a lean operational footprint.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow ZyVersa Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ZyVersa Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ZyVersa Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ZyVersa says cash covers only month to month as 2026 trials near - Stock Titan
ZyVersa says cash covers only month to month as 2026 trials near Stock Titan
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update GlobeNewswire
ZVSA SEC Filings - ZyVersa Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ZVSA SEC Filings - ZyVersa Therapeutics Inc 10-K, 10-Q, 8-K Forms Stock Titan
8-K Filing: ZyVersa Therapeutics, Inc. (ZVSA) (CIK 0001859007) — 8-K
8-K
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo